TMA-6
2,4,6-trimethoxyamphetamine
Lethal interactions
| Combination | Type | Severity | Mechanisms | Confidence |
|---|---|---|---|---|
| MAOIs | Drug class | lethal | 2 | high |
Dangerous interactions
26 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
| Condition | Severity | Note |
|---|---|---|
| Cardiovascular | ||
| uncontrolled hypertension | relative | Uncontrolled hypertension, cardiac arrhythmia, or significant cardiovascular disease. Sympathomimetic effects expected to increase heart rate and blood pressure. |
| Psychiatric | ||
| psychotic disorders | absolute | Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic disorders. Risk of acute psychotic episode precipitation. |
| bipolar disorder | relative | Bipolar I and II disorder. Risk of manic episode precipitation, particularly during or following the prolonged psychedelic experience. |
| Hepatic | ||
| hepatic impairment | relative | Significant hepatic impairment may reduce TMA-6 metabolism, prolonging the already extended duration and increasing risk of adverse effects. |
| Pregnancy & Breastfeeding | ||
| pregnancy and breastfeeding | absolute | Pregnancy and breastfeeding. No safety data exist. Theoretical risks from both serotonergic and sympathomimetic pharmacology. |
| Other | ||
| concurrent MAO inhibitor use | absolute | Concurrent use of any monoamine oxidase inhibitor is absolutely contraindicated due to compounded MAO-A inhibition and extreme serotonin syndrome risk. |
| concurrent SSRI/SNRI use | absolute | Concurrent use of serotonin reuptake inhibitors (SSRIs, SNRIs) is absolutely contraindicated due to serotonin syndrome risk from combined MAO-A inhibition and reuptake blockade. |